Opus Genetics (IRD) EPS (Diluted) Growth (1y) (2017 - 2026)
Powered by 
Analysis
Opus Genetics (IRD) EPS (Diluted) Growth (1y) (2017 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Diluted) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 8.02% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -4.52% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 89.89% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 7.59% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 144.25% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 315.14% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -11.18% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 96.41% |
| 10 | Opus Genetics | 446.86 Mn | 358.05 Mn | - | 37.90% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 37.90% |
| Mar 31, 2026 | -211.89% |
| Dec 31, 2025 | 92.53% |
| Sep 30, 2025 | 14.16% |
| Jun 30, 2025 | 61.06% |
| Mar 31, 2025 | 16.56% |
| Dec 31, 2024 | -492.16% |
| Sep 30, 2024 | -215.98% |
| Jun 30, 2024 | -27.02% |
| Mar 31, 2024 | -4.79% |
| Dec 31, 2023 | -113.48% |
| Sep 30, 2023 | 212.28% |
| Jun 30, 2023 | 6.31% |
| Mar 31, 2023 | 20.79% |
| Dec 31, 2022 | 487.69% |
| Sep 30, 2022 | 11.56% |
| Jun 30, 2022 | 51.82% |
| Mar 31, 2022 | 90.22% |
| Dec 31, 2021 | 89.39% |
| Sep 30, 2021 | 25.02% |